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a b s t r a c tBackground: There is growing consensus that frailty, a state of vulnerability and a decline in functioning across
multiple physiological body systems, is a valuable criterion to guide clinicians' risk prediction for poor outcomes
in adult transplant candidates. In its 2016 listing criteria for heart transplantation the International Society for
Heart Lung Transplantation recommends frailty assessment.We aimed to summarize the usefulness of frailty as-
sessment in heart transplant candidates or recipients reported throughout the literature.
Methods:Weperformed a systematic literature search in PubMed to identify papers reporting on frailty in trans-
plantation, chronic heart failure, and ventricualr assist device implantation published over the last 10 years in En-
glish. Additionally, a hand search was conducted, including manually searching the reference lists and a citation
search of relevant papers.
Results: Elevenprimary research articleswere included in this systematic review. Frailty is a risk factor formorbidity,
hospitalization, and mortality in patients with advanced heart failure and individuals being considered for
ventricualr assist device implantation. Of the patients being considered for transplantation, 33% are frail. The Frailty
Phenotype by Fried is a particularly useful tool to quickly identify higher risk patients for adverse outcomes.
Conclusion:A lackof standardization and limited evidence on frailty in transplantation limit its use as adeﬁnitive list-
ing criterion. Future research efforts should focus on systematic integration of frailtymeasures in transplant practice.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
Frailty is one of the most critical issues for healthcare due to its in-
herent relationship with poor clinical outcomes [1–3]. It has been de-
ﬁned as a cumulative decline across physiological body systems,
depleting a person's ability to maintain homeostasis when faced with
stressors [4–6]. Individuals undergoing organ transplantation face sev-
eral major stressors, and frail transplant patients are more likely to ex-
perience sudden disproportionate deteriorations in health status
comparedwith non-frail patients [4–6]. Following these recent insights,
in their 10-year update of assessment criteria for heart transplantation
the International Society for Heart Lung Transplantation (ISHLT) has
recommended that patients being evaluated for heart transplantation
be assessed for frailty [7]. Frailty assessment is deemed particularly rel-
evant since respectively 20% and 17% of heart transplant candidates and
recipients in theUnited States of America (US) are ≥65 years of age,with⁎ Corresponding author at: Institute of Nursing Science, Faculty of Medicine, University
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0955-470X/© 2017 Elsevier Inc. All rights reserved.similar ﬁgures reported in Europe [8–10]. It is postulated that frailty can
provide an important contribution to the limited evidence base to guide
clinical decision-making for transplant candidacy and optimal clinical
management for this older cohort [11,12]. Since frailty assessment is en-
dorsed by ISHLT, it is timely that transplant clinicians understand the
concept of frailty, its measurement in clinical practice, and outcomes.
Therefore, we aimed to summarize the usefulness of frailty assessment
in heart transplant candidates, recipients, and individuals being consid-
ered for destination therapy. This systematic review is expanding on a
previous work on frailty in heart failure patients [13] to include speciﬁc
new subgroups of populations, and to identify new evidence up to the
present time.
1.1. Frailty: two distinct conceptual models that serve different purposes
Twomain conceptual approaches tomeasuring frailty have been de-
veloped over the past 15 years. Even though there is now broad agree-
ment on the deﬁnitions and conceptualization of the syndrome, there is
no consensus on which instrument is best suited to measure frailty.
[14–16] The Frailty Phenotype (FP) focuses on physical aspects of frailty
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Table 1
Fried frailty phenotype instrument [4].
Domain Assessment and scoring
Grip Strength Assessment: Grip strength as measured by the hand-held Jamar dynamometer (Sammons Preston Inc. Boiling Brook, IL),
which has established test–retest, inter- and intra-rater reliability [68]. Stratiﬁed by gender and body mass index (BMI) quartiles:
Men Cutoff for grip strength (kg) criterion for frailty
BMI ≤ 24 ≤ 29
BMI 24.1–26 ≤ 30
BMI 26.1–29 ≤ 30
BMI N 28 ≤ 32
Women
BMI ≤ 23 ≤ 17
BMI 23.1–26 ≤ 17.3
BMI 26.1–29 ≤ 18
BMI N 29 ≤ 21
Scoring: 1 point if weakness is present.
Walk Time Assessment: stratiﬁed by gender and height (gender-speciﬁc cutoff a medium height).
Men Cutoff for Time to Walk 15 f. criterion for frailty
Height ≤ 173 cm ≥ 7 s
Height N 173 cm ≥ 6 s
Women
Height ≤ 159 cm ≥ 7 s
Height N 159 cm ≥6 s
Scoring: 1 point if slowness is present.
Low level of physical activity Assessment: through 1 closed-ended question: ‘How often do you engage in activities that require a low or moderate level of energy,
such as walking, chores (moderately strenuous), mowing the lawn, raking, gardening, hiking, jogging, exercise cycling, dancing, aerobics,
bowling, golf, tennis, racquetball, calisthenics, swimming. Kcals per week expended are calculated using standardized algorithm,
This variable is stratiﬁed by gender.
Scoring: 1 point if:
Men: Kcals of physical activity per week b383 are frail
Women: Those with Kcals per week b270 are frail
Exhaustion Assessment: the following two statements are read: ‘I felt that everything I did was an effort?’ and ‘I could not get going?’
“How often in the week did you feel that way?” (Answer option: 0 = rarely or none of the time (b 1 day), 1 = some or a little of the time
(1–2 days), 2 = a moderate amount of the time (3–4 days), or 3 = most of the time. A response of “2” or “3” to either one or
both questions is considered as exhaustion and categorized as frail.
Scoring: 1 point if exhaustion is present.
Weight loss Assessment: through 1 closed-ended question: ‘In the last year, have you lost more than 10 lb unintentionally
(i.e., not due to dieting or exercise)?’ (If yes, then frail for weight loss criterion.
Scoring: 1 point if weight loss is present.
Overall score Non-frail: 0 Pre-frail: 1–2 Frail: 3–5
Table 2
Frailty Index.
Domain Assessment
Mobility Walking speed
Number of falls in the past six months
Cognition History of dementia
Mini-Cog Test or Mini-Mental Status Exam
Function Dependency in activities of daily living
Exhaustion Energy level
Burden of chronic disease Charlson Index
N 5 chronic medications
Nutritional status N 10 lb weight loss in the past 6 months
low albumin, poor appetite
Mood Depression, Sadness, Anxiety
Social vulnerability Presence of social support
Lack of interactions with other people
Scoring for frailty: classify each characteristic as present or absent based on standard cut-
off points, sum the number of abnormal frail characteristics and divide by the number of
total assessed characteristics.
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tual framework of frailty, whichwasﬁrst proposed and psychometrical-
ly tested in the Cardiovascular Health Study in 2001, a large cohort
study in community dwelling older adults in the US [4,17–19]. This phe-
notype consists of ﬁve components that capture a decline in physiolog-
ical reserve: (1) unintentional weight loss (10 lb in the past year);
(2) self-reported exhaustion; (3) a low level of physical activity;
(4) slowwalk speed; and (5) reduced grip strength, and categorizes in-
dividuals as non-frail (0/5), pre-frail (1–2/5), or frail (≥3/5) [4–6]. The
FP is a widely used approach for assessing frailty in a variety of chroni-
cally ill populations [20] and is endorsed for integration in the preoper-
ative assessment for older surgical patients by the American College of
Surgeons [16] and the American Geriatric Society [21].
Rockwood and colleagues used the Canadian Study of Health and
Aging to develop and validate the Frailty Index (FI) in 2001 [22–25].
The FI is based on a count of up to 70 deﬁcits, including comorbidities,
physical and cognitive impairments, psychosocial factors and common
geriatric syndromes (e.g. urinary incontinence, fall risk, delirium)
(Table 2) [6,24–26]. The understanding here is that frailty is a condition
that encompasses medical, functional and psychosocial domains, and
deﬁnes an individuals' severity of frailty by the proportion of possible
deﬁcits present [27]. A total score from0.0 (no frailty) to 1.0 (highest se-
verity of frailty) is derived [24].
Frailty measurement is not yet routinely applied in transplantation
and is frequently judged from the end of the bed, under the assumption
“I know it when I see it”. However, this end-of-the-bed assessment is an
inadequate substitution for objectively assessing frailty using standard-
izedmeasurements in acute cardiology and hemodialysis [28,29]. As cli-
nicians tend to underestimate frailty in clinical settings, the use of
standardized, reliable and valid frailty screening and assessment toolsis imperative [28,29]. Many different frailty measurements exist that
have not been extensively validated, applied across various age- and
disease groups, or compared against each other in their capacity to pre-
dict adverse outcomes. This heterogeneity in approaches provides chal-
lenges for clinicians to choose an appropriate instrument to routinely
apply frailty measurement in clinical practice [16,20]. Some authors
suggest that the FI is conceptually less well deﬁned, as deﬁcits captured
include disabilities and comorbidities, concepts which co-occur with,
yet are distinct from frailty [17]. The FP is reported to recognize frailty
as a distinct medical condition that is separate from disability and
F1
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tual model.
2. Methods
2.1. Identiﬁcation of relevant papers
We performed a systematic review of articles published in English
over the last ten years in PubMed, followed by a citation search. A search
string was built combining MeSH terms and free text words related to
‘frailty’ and ‘transplantation’ (Fig. 1). Additionally, the reference lists of
studies meeting eligibility criteria were screened for relevant papers
that might have been missed through the electronic search.
2.2. Selection of relevant papers
We included papers reporting on frailty in heart transplantation,
chronic heart failure and ventricualr assist device (VAD) implantation.
Heart failure patients requiring either bridge-to-transplant or destina-
tion VAD therapy are included in this review due to the very limited ev-
idence pertaining to cardiac transplantation alone. Quantitative studies
were included if a deﬁnedmeasure of frailty was assessed in a cohort of
heart transplant candidates or recipients, heart failure patients, or VAD
recipients. Qualitative studies, doctoral theses, books andbook chapters,
and case studies were excluded.
The titles and abstracts of potentially relevant papers were screened
using the predeﬁned inclusion and exclusion criteria. Then the full
text articles were obtained from all abstracts meeting inclusion criteria
and were further screened for eligibility. Two researchers (OM, VC) in-
dependently performed the selection and inclusion of articles,PubMed
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Fig. 1. Search retriwith differences being resolved through discussion with a third mem-
ber (SRJ).
2.3. Data extraction and summarizing
An initial data-charting format was developed by two researchers
(OM, VC). Iterative discussions within the research team guided small
adjustments during the data charting process. The ﬁnal version entailed
information concerning prevalence, morbidity, and mortality about
frailty in transplantation, chronic heart failure, and VAD implantation.
Data from the included studies were extracted by one researcher
(OM) and double-checked by a second reviewer (VC). Themethodolog-
ical quality of the studies was checked using The Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) instru-
ment of the Equator Network. The review process was reported based
on the guidelines of the Preferred Reporting Items for Systematic Re-
views and Meta-Analysis (PRISMA).
3. Results
The database search produced 1713 articles for screening (Fig. 1).
After screening of titles, abstracts and full texts, 11 studies [30–40]
were included and summarized in this paper (Table 3). Although over
the past 10 years a rapid growing body of evidence has highlighted frail-
ty as a highly prevalent and novel predictor for clinically relevant ad-
verse outcomes in general [20], only one study assessing frailty in
patients referred for heart transplantation could be identiﬁed [30]. Nev-
ertheless, frailty has been examinedmore intensively in the related ﬁeld
of chronic heart failure, as well as mechanical circulatory support im-
plant and is thus included in this review [31–40]., Medline query
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Table 3
Summary of included articles on frailty in cardiac transplantation, including frailty in heart failure, and LVAD therapy and their impact on outcomes.
References,
Country
Design Setting/Sample n Patients Frailty
Measure
Prevalence of
frailty
Clinical Outcomes
Jha et al. [30] Australia Prospective cohort Outpatients referred for
transplant assessment
120 53 ± 12 years;
83% males
Modiﬁed FP 33% Mortality HR 2.07 (95% CI; 1.01–4.26
Madan et al. [31] USA Single-center
pilot study
Outpatients with CHF 40 74.9 ± 6.5 years;
42% males
FP 65% All-cause hospitalization HR 1.92 (CI 95% 1.12–3.27; P = 0.017)
Non-HF hospitalizations HR 3.31 (95% CI 1.14–9.6; P = 0.380)
Mortality HR 1.93 (95% CI; 1.15–3.25,
P = 0.013)
Reeves et al. [32] Prospective
3 age-matched
cohort
Patients hospitalized with acute
decompensated heart failure
(HF)
matched with a) stable HF with
preserved EF, b) stable HF with
reduced EF, c) healthy
older adults
27 72.9 ± 10 years;
41% males
FP 56% Severe reduction in all domains of physical function,
with≈50% lower in acute decompensated heart failure
patients than in stable heart failure or healthy older adults.
Vidan et al. [33] Prospective cohort Patients hospitalized for
heart failure
450 80 ± 6 years;
50.5% males
FP 76% Higher risk for functional decline [OR 2.20, 95% CI 1.19–4.08], 1-year
all-cause mortality [HR 2.13, 95% CI 1.07–4.23] and 1-year hospital
readmission [OR 1.96, 95% CI 1.14–3.34].
Lupon et al. [34] Observational Study Outpatients with CHF 622 68 (29–93) years;
72.5% males
Comprehensive
geriatric assessment
40% HR 2.09 (95% CI 1.11–3.92
q = 0.022 for 1-year mortality
Khan et al. [35] USA Secondary analysis Community dwelling elders 2825 74 ± 3 years;
48% males
Healthy aging and
body
composition & Gill
index
18% Moderate (HR 1.36 95% CI 1.08–1.710) and severe
(HR 1.88, 95% CI 1.02–3.47) frailty increased the risk of HF
McNallan et al. [36]
USA
Observational study Community dwelling
CHF patients
223 71 ± 14 years; 61%
males
FP and deﬁcit index FP: 21% DI: 0.02–
0.075 (± 0.25)
Mortality; FP: HR 2.04 (95% CI 0.99–4.16, q = 0) DI: HR 1.44
(95% CI 1.18–1.76; q = 0)
Highly co-morbid: N60% patients had a CCI C3
Boxer et al. [37] Prospective cohort Outpatients with CHF 60 78 ± 12 years; 72%
males
FP 27% HR 1.64 (95% CI 1.19–2.26; q = 0.005)
Pulignano et al. [38]
Italy
RCT Outpatients with CHF 173 UC: n = 87; 78 ±
6 years; 53% males
DMP: n = 86
77 ± 6 years; 51% males
Modiﬁed frailty score Higher 1-year mortality (16.9 vs. 4.8%; P b 0.001)
Higher rate of hospitalization (20.5 vs. 13.3%; P = 0.01)
Dunlay et al. [39] Prospective
cohort study
Patients undergoing
LVAD implant
99 65.1 ± 9.4 years;
72% males
Frailty deﬁcit index 29% Rehospitalization intermediate frail HR 1.70 (95% CI 1.23–2.34) and
1.42 (95% CI 0.98–2.06) for frail.
Intermediate frail (HR 1.70 95% CI 0.71–4.31) and frail
(HR 3.08, 95% CI 1.40–7.48) were at risk for death
Chung et al. [40] Observational
cohort study
Patients with advanced HF
undergoing VAD implantation
72 59 ± 2 years; 64% males Hand grip strength a
component of FP
Handgrip strength of b25% of body weight showed increased
postoperative complications and mortality (bleeding 54 vs 17%; and
infections 85 vs 54%), and a lower 6 months survival after the device
implant (75.0 vs 92.9%) that persisted up to 3 years following LVAD
implant
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3.1.1. Prevalence
Jha et al. [30] assessed frailty in 120 patients (69% men; mean age
53 ± 12 years, mean left ventricular ejection fraction 27 ± 14%), with
advancedheart failure referred for cardiac transplantation, using amod-
iﬁed version of the Fried's phenotype, and found that 33% of the patients
were frail. Prevalence of frailty was independent of age, gender, heart
failure duration, left ventricular ejection fraction, or renal function
[30]. In the study by Madan et al. [31] 65% of patients in a heart failure
clinicwere found to be frail based on the Fried Frailty Phenotype. Reeves
and colleagues [32] prospectively conducted amultidimensional assess-
ment (including frailty based on Fried's phenotype) of 27 patients ≥60
years of age that had been admitted with acute decompensated heart
failure. The team compared study participants' functional performance
to 3 agematched cohorts: 1) stable heart failurewith preserved ejection
fraction, 2) stable heart failure with reduced ejection fraction, and
3) healthy older adults previously enrolled as outpatients. Frailty was
common, present in N50% of participants with acute decompensated
heart failure, but was rare or absent in the other cohorts (0% to 14% de-
pending on the cohort) [32]. Vidán and colleagues [33] reported that
75% of non-dependent patients ≥70 years of age that were hospitalized
for heart failure fulﬁlled frailty criteria. A study by Lupon et al. [38] em-
phasized that frailty ismore prevalent in older heart failure patients, but
could also be observed in younger individuals (b70 years old) with
chronic heart failure.
3.1.2. Morbidity and mortality
Khan et al. [35], demonstrate that moderate and severe frailty in-
creased the risk for heart failure incidence (HR 1.36; 95% CI 1.08–1.71
and HR 1.88; 95% CI 1.02–3.47, respectively). Another study conducted
by McNallen et al. [36] included community-dwelling individuals with
chronic heart failure, of which over 60% had multiple co-morbidities
in the presence of frailty, which increased the disease burden. Similarly,
in the study by Reeves et al. [32] patients admitted to hospital with
heart failure had a severe reduction in all domains of physical function,
with scores on the 3 measures of physical functioning (6-min walk dis-
tance, Short Physical PerformanceBattery and gait speed) being approx-
imately 50% lower in the patients with acute decompensated heart
failure than in the three age-matched outpatient cohorts (two with sta-
ble heart failures and one with health older adults).
There have been few studies investigating the impact of frailty on
mortality in chronic heart failure patients, and only one within cardiac
transplantation [13]. Speciﬁcally, a study by Jha et al. [30] included
120 heart failure patients on thewaiting list for transplantation, and re-
ported that frailty was an independent predictor of all-cause mortality,
with a mean one year survival of 79% ± 5% in the non-frail group com-
pared with 54% ± 9% in the frail group (P b 0.005). Madan et al. [31]
demonstrated that the frailty status of heart failure patients was associ-
ated with mortality and all-cause hospitalization (HR 1.93; 95% CI
1.15–3.25, P= .031) [31]. Boxer and colleagues [37] followed sixty com-
munity dwelling patients with heart failure (EF ≤ 40%) in a heart failure
center, demonstrating that frailty scores were independently predictive
of mortality [HR 1.64, 95% CI 1.19–2.26]. Vidán et al. [33] reported that
frail individuals ≥70 years of age whowere hospitalized for heart failure
showed a higher risk for functional decline [OR 2.20, 95% CI 1.19–4.08],
1-year all-causemortality [HR 2.13, 95% CI 1.07–4.23] and 1-year hospi-
tal readmission [OR 1.96, 95%CI 1.14–3.34] than thenonfrail/normal en-
durance group. Similarly, a study by Pulignano et al. [38] showed a
signiﬁcantly higher rate of hospitalization of frail individuals than in
less frail patients (frailty score b 2) (21 versus 13%; P = 0.01). Studies
in our review highlight that frailty assessment provides valuable prog-
nostic insights in addition to existing risk prediction models.
Concomitantly, many patients with severe heart failure have non-
cardiac related comorbidities that render them ineligible for cardiac
transplantation and are therefore considered for destination therapy.Dunlay et al. [39] reported that pre-operative frailty assessment, using
the Frailty Index, is associatedwithworse outcomes following LVAD im-
plant as destination therapy. Patients who were frail at the time of an
LVAD implant had an increased risk for mortality (HR 3.08; 95% CI
1.40–7.48). Hazard ratio for re-hospitalization was 1.70 (95% CI
1.23–2.34) for intermediate frail patients, and 1.42 (95% CI 0.98–2.06)
in those who were frail (based on tertiles of the deﬁcit index N0.32 =
frail, 0.23 to 0.32 = intermediate frailty, b0.23 = not frail) [39]. Find-
ings indicate that the risk to be re-hospitalized following device implant
is higher in individuals with intermediate frailty. Chung et al. [40] mea-
sured handgrip strength, amarker of frailty that is often part of the frail-
ty scoring system, in 72 heart failure patients undergoing VAD implant.
Study participants with a handgrip strength of b25% of body weight
showed increased postoperative complications and mortality (bleeding
54% vs 17%; and infections 85% vs 54%), and a lower 6 months survival
after the device implant (75.0% vs 92.9%) that persisted up to 3 years fol-
lowing VAD implant.
4. Discussion
The important clinical aspect for transplant professionals is that
older individuals with multiple comorbidities require a better risk as-
sessment when evaluating transplant candidacy. Frailty enables clini-
cians to focus on patients' biological age and has important
implications for adverse health outcomes and is being endorsed by var-
ious organizations to improve quality of care [16,21]. Of importance, the
magnitude of risks associated with frailty, increased comorbidities, and
mortality is greater than from current risk predictions. Screening pa-
tients using an assessment tool based on the FP is endorsed by the
ISHLT and can classify transplant candidates into new and clinically
meaningful risk categories. In the management of patients with chronic
conditions, disentangling frailty from comorbidities through the FP
might be important when assessing chronically ill individuals for trans-
plantation. FP as a screening tool to enhance risk stratiﬁcation for ad-
verse outcomes in clinical practice is feasible, since no prior clinical
information is needed and it takes 10 to 15 min to complete [18,20].
At the same time, assessments based on the FP do not provide insights
into underlying factors contributing to a patient's frailty, and thus pro-
vide limited guidance towards preventive or therapeutic interventions
when frailty is identiﬁed. This is a drawback that is addressed by the
FI, given its assessment of speciﬁc deﬁcits across various domains, en-
abling clinicians to modify certain aspects of a patient's care to poten-
tially improve frailty. The major disadvantage of the FI is however that
it requires a comprehensive geriatric assessment for its scoring, which
renders its evaluation time-consuming [41]. It is of key importance for
clinicians to understand that the FP and FI cannot be considered equiv-
alent. The optimal choice of approach depends on the purpose, e.g.
whether a frailty screening for risk stratiﬁcation (FP), or a more thor-
ough frailty assessment to tailor patient care is intended (FI).
Risk stratiﬁcation for frail transplant candidates and recipients, also
requires evidence for feasible, effective and scalable interventions to
prevent frailty, or to slow its progress. A hallmark of frailty is that the
condition can deteriorate or improve over time [5,42–44]. At this
point the optimal time to start an intervention to improve frailty is
still not clear, especially for individuals being listed for transplantation.
Given the fact that it is easier to improve small deﬁcits, rather than larg-
er ones it is recommended to focus on improving patient's functional
status when they are pre-frail, rather than frail. Incorporating frailty
screening would allow healthcare professionals to systematically iden-
tify pre-frail individuals when listing them for cardiac transplantation
and initiate pre-rehabilitation. Pre-rehabilitation has shown to result
in fewer complications following surgical procedures, as well as de-
creased hospital stay in non-transplant populations [45]. Also without
intervention worsening frailty in older non-transplant populations is
common. Since cardiac rehabilitation has been shown to decrease mor-
tality and morbidity in patients with heart failure in both hospital and
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improve an individual's frailty status prior to transplantation.When pa-
tients have been enrolled in pre-rehabilitation further frailty assess-
ments could be conducted to capture when a patient has achieved
optimal beneﬁt from the program. Although behavioral interventions
focusing on physical activity and/or exercise show potential to improve
clinical outcomes [5,6,18,46–50], no interventions have focused speciﬁ-
cally on individuals with end stage organ failure and transplant recipi-
ents to mitigate effects of frailty.
In addition to building on behavior change science, suchwork needs
to include a better understanding of underlying pathophysiological pro-
cesses that impact frailty and its interrelationship with cognitive func-
tion. Current biological frameworks of frailty etiology point to the
dysregulation of several key physiological systems, including the neuro-
endocrine, musculoskeletal, metabolic and immune/inﬂammatory
system [51]. Recent longitudinal studies in various cohorts of older
non-transplant adults suggest the latter as a key pathway [6,52–55].
Complex alterations in the innate and adaptive immune system are hy-
pothesized to create a state of chronic low-grade systemic inﬂamma-
tion, which induces frailty and a higher susceptibility for chronic
conditions, disability and mortality [51]. Causality of the inﬂammatory
pathway in frailty has to date only scarcely been explored [49,56,57].
Moreover, evidence on a similar etiological pathway for mild cognitive
impairment (MCI) is emerging [58] with one recent study identifying
that MCI (assessed using the Montreal Cognitive Assessment Tool)
was present in 64% of heart failure patients who were frail pre-
transplant and in 33% of those who were not physically frail [59]. Stud-
ies in patients with end-stage heart failure that incorporated cognitive
assessment in the FP improve its predictive validity for adverse out-
comes [59]. Research has illuminated that MCI can accelerate the devel-
opment of disability, which is predictive of hospitalization andmortality
[60–63]. Thus, research exploring the interrelationships of frailty and
MCI, their evolution, and joint predictive ability for negative outcomes
is essential to advance frailty-screening methods [58,64]. At this point,
transplant candidates with cognitive impairments are best followed
up with a geriatric assessment to determine the cause of cognitive de-
cline, followed by a personal, evidence based, multimodal intervention.
Additionally, studies show that frail patients use more healthcare
resources compared to robust individuals. Frailty has therefore been
recognized as a long-term condition leading to a range of adverse
outcomes for individual patients and high healthcare expenses for the
wider society [36,43,65–67]. Thus, research is needed to examine the
impact of frailty on resource use and the cost-effectiveness of
transplantation.
5. Conclusion
This systematic review demonstrates that frailty assessment in heart
transplant candidates, as well as heart failure patients requiring me-
chanical circulatory support, is feasible and provides clinical prognostic
value. Yet, its practical translation into transplant medicine is in its in-
fancy. The evidence on poor outcomes of frail transplant candidates
and a potential increased economic burden suggest an urgent need for
transplant professionals to pay attention to the syndrome. Nevertheless,
there is a need for more studies investigating frailty in the ﬁeld of cardi-
ac transplantation to allow any ofﬁcial recommendation for transplant
list eligibility.
The authors declare no conﬂicts of interest. This state of the art sys-
tematic review was conducted without speciﬁc funding sources.
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